<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274325</url>
  </required_header>
  <id_info>
    <org_study_id>si446/2010</org_study_id>
    <nct_id>NCT01274325</nct_id>
  </id_info>
  <brief_title>Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma</brief_title>
  <official_title>Comparison of Anti-inflammatory Effects of Seroflo 125 Inhaler With Seretide Evohaler(25/125) in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test hypothesis if Sereflo (ICS/LABA) could reduce airway
      inflammation in asthmatic patients in the same as Seretide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum eosinophils</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control test scores</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sereflo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sereflo (25/125)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seretide (25/125)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sereflo</intervention_name>
    <description>Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks</description>
    <arm_group_label>Sereflo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide</intervention_name>
    <description>Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks</description>
    <arm_group_label>Seretide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20-80 years

          -  Patients with asthma diagnosed by according to the American Thoracic Society criteria

          -  A baseline FEV1 &gt; or = 50% predicted with a reversibility of FEV1 after therapy with
             inhaled salbuterol (2.5 mg) of FEV1 12% or with provocative concentration of a
             methacholine causing a 20% fall in FEV1 (PC20) of &lt; or = 8 mg/mL

          -  Prescribed use of inhaled corticosteroids (any brand) for at least 12 weeks prior to
             study entry

          -  The daily prescribed dose of inhaled corticosteroids during the last 4 weeks prior to
             study entry should have been constant and at least 250 μg/day of fluticasone at least
             400 μg/day of budesonide at least 500 μg/day of any other beclomethasone

          -  Be able to provide written informed consent

        Exclusion Criteria:

          -  Any asthma exacerbation or respiratory tract infection affecting asthma within 4 weeks
             prior to the randomization visit

          -  Intake of oral, parenteral corticosteroids within 4 weeks and/or depot parenteral
             corticosteroid within 12 weeks prior to the randomization visits

          -  Current or previous smoker with a smoking history of &gt; or = 10 pack years

          -  Previous randomization of treatment in the present study

          -  Known or suspected hypersensitivity to study therapy

          -  Use of any β-blocking agent, including eye-drops

          -  Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not
             using acceptable contraceptive pill measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kittipong Maneechotesuwan, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Siriraj Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kittipong Maneechotesuwan</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Respiratory Disease and TB, Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>BKK</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Kittipong Maneechotesuwan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

